| Literature DB >> 19798418 |
Erno Lindfors1, Peddinti V Gopalacharyulu, Eran Halperin, Matej Oresic.
Abstract
Recent clinical evidence suggests important role of lipid and amino acid metabolism in early pre-autoimmune stages of type 1 diabetes pathogenesis. We study the molecular paths associated with the incidence of insulitis and type 1 diabetes in the Non-Obese Diabetic (NOD) mouse model using available gene expression data from the pancreatic tissue from young pre-diabetic mice. We apply a graph-theoretic approach by using a modified color coding algorithm to detect optimal molecular paths associated with specific phenotypes in an integrated biological network encompassing heterogeneous interaction data types. In agreement with our recent clinical findings, we identified a path downregulated in early insulitis involving dihydroxyacetone phosphate acyltransferase (DHAPAT), a key regulator of ether phospholipid synthesis. The pathway involving serine/threonine-protein phosphatase (PP2A), an upstream regulator of lipid metabolism and insulin secretion, was found upregulated in early insulitis. Our findings provide further evidence for an important role of lipid metabolism in early stages of type 1 diabetes pathogenesis, as well as suggest that such dysregulation of lipids and related increased oxidative stress can be tracked to beta cells.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19798418 PMCID: PMC2749452 DOI: 10.1371/journal.pone.0007323
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Enriched molecular path detection concept.
Illustrative example of path detection in a complex network of interacting entities. An enriched path of 6 entities is highlighted.
Figure 2Selected paths significant in different case-control settings.
Upregulated (A) and downregulated (B) paths related to insulitis. Upregulated (C) and downregulated (D) paths related to late insulitis and T1D.
Top enriched pathways in insulitis and type 1 diabetes as derived from detected paths.
| Gene set | Source | n(P & G) | n(G) | Nominal | FDR |
|
| |||||
| PTDINSPATHWAY | BioCarta | 3 | 19 | 0.000004 | 0.000103 |
| HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM | KEGG | 3 | 27 | 0.000012 | 0.000155 |
| HSA00530_AMINOSUGARS_METABOLISM | KEGG | 2 | 16 | 0.000025 | 0.000280 |
| GALACTOSE_METABOLISM | GenMAPP | 2 | 20 | 0.000596 | 0.003099 |
| HSA00052_GALACTOSE_METABOLISM | KEGG | 2 | 24 | 0.000863 | 0.003738 |
| GLUCONEOGENESIS | GenMAPP | 2 | 39 | 0.002286 | 0.006604 |
| GLYCOLYSIS | GenMAPP | 2 | 39 | 0.002286 | 0.006604 |
| HSA04630_JAK_STAT_SIGNALING_PATHWAY | KEGG | 4 | 100 | 0.000118 | 0.008023 |
| HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY | KEGG | 3 | 62 | 0.000150 | 0.008426 |
| GHPATHWAY | BioCarta | 2 | 24 | 0.000863 | 0.016104 |
|
| |||||
| GLYCEROLIPID_METABOLISM | GenMAPP | 3 | 24 | <10−6 | 0.000011 |
| STATIN_PATHWAY_PHARMGKB | GenMAPP | 2 | 16 | 0.000152 | 0.000557 |
| HSA00565_ETHER_LIPID_METABOLISM | KEGG | 2 | 21 | 0.000441 | 0.002093 |
| HSA00071_FATTY_ACID_METABOLISM | KEGG | 2 | 29 | 0.000847 | 0.002311 |
| HSA00120_BILE_ACID_BIOSYNTHESIS | KEGG | 2 | 20 | 0.000399 | 0.002311 |
| HSA00220_UREA_CYCLE_AND_METABOLISM_OF_AMINO_GROUPS | KEGG | 2 | 21 | 0.000441 | 0.002311 |
| HSA00310_LYSINE_DEGRADATION | KEGG | 2 | 29 | 0.000847 | 0.002311 |
| HSA00340_HISTIDINE_METABOLISM | KEGG | 2 | 19 | 0.000359 | 0.002311 |
| HSA00410_BETA_ALANINE_METABOLISM | KEGG | 2 | 17 | 0.000286 | 0.002311 |
| HSA00620_PYRUVATE_METABOLISM | KEGG | 2 | 28 | 0.000789 | 0.002311 |
|
| |||||
| EGFPATHWAY | BioCarta | 4 | 25 | <10−6 | 0.000040 |
| HSA04630_JAK_STAT_SIGNALING_PATHWAY | KEGG | 5 | 100 | 0.000002 | 0.000102 |
| HSA05213_ENDOMETRIAL_CANCER | KEGG | 4 | 42 | 0.000004 | 0.000128 |
| HSA05223_NON_SMALL_CELL_LUNG_CANCER | KEGG | 4 | 43 | 0.000004 | 0.000128 |
| CTLA4PATHWAY | BioCarta | 3 | 15 | 0.000008 | 0.000131 |
| ERK5PATHWAY | BioCarta | 3 | 16 | 0.000010 | 0.000131 |
| HSA05214_GLIOMA | KEGG | 4 | 50 | 0.000007 | 0.000131 |
| PTENPATHWAY | BioCarta | 3 | 16 | 0.000010 | 0.000131 |
| NGFPATHWAY | BioCarta | 3 | 17 | 0.000012 | 0.000140 |
| IGF1PATHWAY | BioCarta | 3 | 18 | 0.000014 | 0.000149 |
|
| |||||
| PYRIMIDINE_METABOLISM | GenMAPP | 3 | 43 | 0.000010 | 0.000061 |
| HSA00230_PURINE_METABOLISM | KEGG | 3 | 90 | 0.000096 | 0.000334 |
| NDKDYNAMINPATHWAY | BioCarta | 2 | 16 | 0.000898 | 0.006367 |
| HSA05110_CHOLERA_INFECTION | KEGG | 1 | 31 | 0.039815 | 0.046451 |
Top ten enriched gene sets at FDR q<0.05 defined in the Molecular Signature Database [19], using the gene lists derived from the detected paths (Figures S2– S5). The p-value is obtained from the hypergeometric test. Column legend: n(P&G), number of common genes in the detected path and the gene set; n(G), number of genes in the gene set.
Top scored pathways in GSEA.
| Gene set | Size | Enrichment Score | Nominal p-value | FDR q-value | Source |
|
| |||||
| HSA03010_RIBOSOME | 44 | −0.61 | 0.000466 | 0.0027 | KEGG |
| WNTPATHWAY | 22 | −0.63 | 0.002375 | 0.0252 | BioCarta |
| HSA00071_FATTY_ACID_METABOLISM | 29 | −0.58 | 0.001845 | 0.0291 | KEGG |
| CALCINEURINPATHWAY | 17 | −0.64 | 0.007370 | 0.0392 | BioCarta |
| PROTEASOMEPATHWAY | 21 | −0.61 | 0.004710 | 0.0418 | BioCarta |
| BILE_ACID_BIOSYNTHESIS | 15 | −0.65 | 0.007466 | 0.0425 | GenMAPP |
|
| |||||
| HSA04610_COMPLEMENT_AND_COAGULATION_CASCADES | 52 | 0.62 | <10–5 | 0.0022 | KEGG |
| HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION | 33 | 0.66 | <10–5 | 0.0038 | KEGG |
| HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | 74 | 0.54 | <10–5 | 0.0107 | KEGG |
| HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 169 | 0.47 | <10–5 | 0.0183 | KEGG |
| NKCELLSPATHWAY | 15 | 0.71 | 0.002838 | 0.0310 | BioCarta |
| HSA04940_TYPE_I_DIABETES_MELLITUS | 20 | 0.66 | 0.002753 | 0.0353 | KEGG |
|
| |||||
| CELL_CYCLE_KEGG | 58 | −0.57 | <10–5 | 0.0031 | GenMAPP |
| CELL_CYCLE | 53 | −0.56 | <10–5 | 0.0073 | GO |
| UBIQUITIN_MEDIATED_PROTEOLYSIS | 20 | −0.67 | 0.000937 | 0.0096 | GenMAPP |
| G1_TO_S_CELL_CYCLE_REACTOME | 54 | −0.53 | <10–5 | 0.0112 | GenMAPP |
| HSA00190_OXIDATIVE_PHOSPHORYLATION | 86 | −0.49 | <10–5 | 0.0113 | KEGG |
| P53PATHWAY | 16 | −0.70 | 0.001388 | 0.0144 | BioCarta |
| PROTEASOMEPATHWAY | 21 | −0.64 | <10–5 | 0.0174 | BioCarta |
| HSA04120_UBIQUITIN_MEDIATED_PROTEOLYSIS | 25 | −0.62 | 0.000473 | 0.0177 | KEGG |
| HSA04110_CELL_CYCLE | 82 | −0.47 | 0.000553 | 0.0211 | KEGG |
| CARM_ERPATHWAY | 19 | −0.63 | 0.004144 | 0.0279 | BioCarta |
| MRNA_PROCESSING_REACTOME | 83 | −0.46 | <10–5 | 0.0312 | GenMAPP |
| HSA00510_N_GLYCAN_BIOSYNTHESIS | 24 | −0.59 | 0.003738 | 0.0356 | KEGG |
| G2PATHWAY | 18 | −0.62 | 0.004585 | 0.0475 | BioCarta |
This table contains top scored gene sets in GSEA for each strain (FDR q<0.05). The gene sets studies are the same as in the analysis for Table 1. None of the pathways were significantly upregulated in the BDC2.5/NOD vs. NOD comparison using the FDR q<0.05 threshold.
Figure 3Schematic representation of the steps involved in the biosynthesis of ether phospholipids, including plasmalogens.
The lipids found consistently downregulated in serum of children who later developed type 1 diabetes [3] are shown in green box. DHAPAT enzyme is found in the downregulated paths in early insulitis in the present study (green arrow). The first three reactions in the pathway take place in peroxisomes, while the others are catalyzed by microsomal enzyme systems. Other routes for the formation of ether phospholipids may exist [16].